In AI-enabled drug discovery, there might be more than one winner

W
elcome to the TechCrunch Exchange, a weekly startups-and-markets newsletter. It’s inspired by the daily TechCrunch+ column where it gets its name. Want it in your inbox every Saturday? Sign up here.

Today, a look at Israel from three different angles: drug discovery, AI-enabled cybersecurity threats, and investor reactions to the political crisis. — Anna

From spatial biology to proteomics

Chipmaker Nvidia invested $50 million into biotech startup Recursion, which now plans to “accelerate [the] development of its AI foundation models for biology and chemistry,” according to a press release.

Recursion CTO Ben Mabey said the company aims to build “a definitive foundation model for the drug discovery space.” That’s no easy feat; its CEO Chris Gibson referred to drug discovery as “one of the world’s most difficult challenges.”

However, both Recursion and Nvidia hope AI can help solve this challenge. “Generative AI is a revolutionary tool to discover new medicines and treatments,” Nvidia CEO Jensen Huang wrote in a canned statement.

Recursion is far from the only company working on this; in May, it acquired two companies in the AI-enabled drug discovery space, Cyclica and Valence. But while these three companies are headquartered in North America, I couldn’t help but notice that a number of their competitors are based in Israel.

I asked Lior Handelsman and Renana Ashkenazi, two general partners at Israeli VC firm Grove Ventures, why Israel may be an AI-enabled biotech hotbed. They mentioned some factors I was expecting, such as academic talent and the entrepreneurial spirit that already turned the country into a Startup Nation. But Ashkenazi also noted that the profile of biotech founders is changing.

It’s encouraging to think that multiple startups will find ways to leverage AI and other fields to accelerate drug discovery and improve patient outcome. Read More TechCrunch

Disclaimer

Innov8 is owned and operated by Rolling Rock Ventures. The information on this website is for general information purposes only. Any information obtained from this website should be reviewed with appropriate parties if there is any concern about the details reported herein. Innov8 is not responsible for its contents, accuracies, and any inaccuracies. Nothing on this site should be construed as professional advice for any individual or situation. This website includes information and content from external sites that is attributed accordingly and is not the intellectual property of Innov8. All feeds ("RSS Feed") and/or their contents contain material which is derived in whole or in part from material supplied by third parties and is protected by national and international copyright and trademark laws. The Site processes all information automatically using automated software without any human intervention or screening. Therefore, the Site is not responsible for any (part) of this content. The copyright of the feeds', including pictures and graphics, and its content belongs to its author or publisher. Views and statements expressed in the content do not necessarily reflect those of Innov8 or its staff. Care and due diligence has been taken to maintain the accuracy of the information provided on this website. However, neither Innov8 nor the owners, attorneys, management, editorial team or any writers or employees are responsible for its content, errors or any consequences arising from use of the information provided on this website. The Site may modify, suspend, or discontinue any aspect of the RSS Feed at any time, including, without limitation, the availability of any Site content. The User agrees that all RSS Feeds and news articles are for personal use only and that the User may not resell, lease, license, assign, redistribute or otherwise transfer any portion of the RSS Feed without attribution to the Site and to its originating author. The Site does not represent or warrant that every action taken with regard to your account and related activities in connection with the RSS Feed, including, without limitation, the Site Content, will be lawful in any particular jurisdiction. It is incumbent upon the user to know the laws that pertain to you in your jurisdiction and act lawfully at all times when using the RSS Feed, including, without limitation, the Site Content.